Published in Retrovirology on May 09, 2012
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis (2012) 1.02
Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol (2013) 0.99
Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS (2013) 0.94
Using nonhuman primates to model HIV transmission. Curr Opin HIV AIDS (2013) 0.91
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr (2015) 0.90
Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate. J Acquir Immune Defic Syndr (2016) 0.77
Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs. PLoS One (2016) 0.75
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol (2007) 168.76
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A (2004) 20.53
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science (1999) 4.09
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol (2001) 3.20
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol (2006) 2.19
A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol (2010) 1.84
Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci (2009) 1.48
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses (1997) 1.15
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2011) 1.05
Generation of a dual RT Env SHIV that is infectious in rhesus macaques. J Med Primatol (2010) 0.85
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Naturally acquired simian retrovirus infections in central African hunters. Lancet (2004) 5.34
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol (2009) 2.96
Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A (2005) 2.86
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76
Ancient co-speciation of simian foamy viruses and primates. Nature (2005) 2.71
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol (2013) 2.59
Defects in SPT16 or POB3 (yFACT) in Saccharomyces cerevisiae cause dependence on the Hir/Hpc pathway: polymerase passage may degrade chromatin structure. Genetics (2002) 2.54
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol (2004) 2.44
Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep (2005) 2.35
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A (2010) 2.25
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol (2006) 2.10
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One (2007) 2.09
Detection of novel SARS-like and other coronaviruses in bats from Kenya. Emerg Infect Dis (2009) 2.04
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99
Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis (2004) 1.98
Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. PLoS Pathog (2008) 1.92
Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev (2010) 1.89
Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol (2006) 1.83
High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr (2011) 1.74
A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol (2003) 1.63
High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS (2007) 1.62
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Exceptional simian hemorrhagic fever virus diversity in a wild African primate community. J Virol (2012) 1.53
HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother (2008) 1.52
Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci (2009) 1.48
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One (2012) 1.42
Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology (2011) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38
Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol (2003) 1.38
Demographic but not geographic insularity in HIV transmission among young black MSM. AIDS (2011) 1.37
Clinical and virological characterization of persistent human infection with simian foamy viruses. AIDS Res Hum Retroviruses (2007) 1.32
Structural features of nucleosomes reorganized by yeast FACT and its HMG box component, Nhp6. Mol Cell Biol (2004) 1.32
Cross-species retroviral transmission from macaques to human beings. Lancet (2002) 1.30
A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old World primate. J Virol (2013) 1.30
HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS (2004) 1.29
Zoonotic viruses associated with illegally imported wildlife products. PLoS One (2012) 1.29
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28
Coinfection of Ugandan red colobus (Procolobus [Piliocolobus] rufomitratus tephrosceles) with novel, divergent delta-, lenti-, and spumaretroviruses. J Virol (2009) 1.27
Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol (2002) 1.24
HIV transmission in a state prison system, 1988-2005. PLoS One (2009) 1.24
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS One (2011) 1.19
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis (2011) 1.19
Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. J Gen Virol (2004) 1.18
Ancient, independent evolution and distinct molecular features of the novel human T-lymphotropic virus type 4. Retrovirology (2009) 1.16
Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J Chromatogr Sci (2009) 1.16
Beyond bushmeat: animal contact, injury, and zoonotic disease risk in Western Uganda. Ecohealth (2014) 1.13
Characterization and comparison of recombinant simian immunodeficiency virus from drill (Mandrillus leucophaeus) and mandrill (Mandrillus sphinx) isolates. J Virol (2003) 1.13
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol (2011) 1.11
Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J Virol (2006) 1.10
Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. Mol Biochem Parasitol (2004) 1.10
Preserving blood safety against emerging retroviruses. Transfusion (2006) 1.09
A rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase. AIDS Res Hum Retroviruses (2006) 1.08
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology (2010) 1.07
Identification and molecular characterization of new STLV-1 and STLV-3 strains in wild-caught nonhuman primates in Cameroon. Virology (2007) 1.07
On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.06
Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS (2014) 1.06
A history of recurrent positive selection at the toll-like receptor 5 in primates. Mol Biol Evol (2009) 1.05
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol (2006) 1.05
Discovery and full genome characterization of two highly divergent simian immunodeficiency viruses infecting black-and-white colobus monkeys (Colobus guereza) in Kibale National Park, Uganda. Retrovirology (2013) 1.05
SHIV susceptibility changes during the menstrual cycle of pigtail macaques. J Med Primatol (2014) 1.05
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2011) 1.05
Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother (2009) 1.04